Re-evaluating currently available data and suggestions for planning randomised controlled studies regarding the use of hydroxyethyl starch in critically ill patients - a multidisciplinary statement
Authors:
- Patrick MeybohmPMPatrick Meybohm
- Hugo Van AkenHAHugo Van Aken
- Andrea De GasperiAGAndrea De Gasperi
- Stefan De HertSHStefan De Hert
- Giorgio Della RoccaGRGiorgio Della Rocca
- Armand Rj GirbesAGArmand Rj Girbes
- Hans GombotzHGHans Gombotz
- Bertrand GuidetBGBertrand Guidet
- Walter HasibederWHWalter Hasibeder
- Markus W HollmannMHMarkus W Hollmann
- Can InceCICan Ince
- Matthias JacobMJMatthias Jacob
Open Access
- 26 July 2013
- journal article
- Published by Springer Nature in Critical Care
- Vol. 17 (4) , R166
Abstract
Introduction: Hydroxyethyl starch (HES) is a commonly used colloid in critically ill patients. However, its safety has been questioned in recent studies and meta-analyses. Methods: We re-evaluated prospective randomised controlled trials (RCT) from four meta-analyses published in 2013 that compared the effect of HES with crystalloids in critically ill patients, focusing on the adherence to 'presumably correct indication'. Regarding the definition of 'presumably correct indication', studies were checked for the following six criteria (maximum six points): short time interval from shock to randomisation (<6 h), restricted use for initial volume resuscitation, use of any consistent algorithm for haemodynamic stabilisation, reproducible indicators of hypovolaemia, maximum dose of HES, and exclusion of patients with pre-existing renal failure or renal replacement therapy. Results: Duration of fluid administration ranged from 90 min up to a maximum of 90 days. Four studies considered follow-up until 90-day mortality, three studies 28-/30-day mortality, whereas four studies reported only early mortality. Included studies showed a large heterogeneity of the indication score ranging between 1 and 4 points with a median (25%; 75% quartile) of 4 (2; 4). Conclusions: The most important question, whether or not HES may be harmful when it is limited to immediate haemodynamic stabilisation, cannot be answered yet in the absence of any study sufficiently addressing this question. In order to overcome the limitations of most of the previous studies, we now suggest an algorithm emphasising the strict indication of HES. Additionally, we give a list of suggestions that should be adequately considered in any prospective RCT in the field of acute volume resuscitation in critically ill patients.Keywords
This publication has 37 references indexed in Scilit:
- Hydroxyethyl Starch or Saline for Fluid Resuscitation in Intensive CareNew England Journal of Medicine, 2012
- Hydroxyethyl Starch 130/0.42 versus Ringer's Acetate in Severe SepsisNew England Journal of Medicine, 2012
- The intravascular volume effect of Ringer's lactate is below 20%: a prospective study in humansCritical Care, 2012
- Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS studyCritical Care, 2012
- Fluid resuscitation in septic shock: A positive fluid balance and elevated central venous pressure are associated with increased mortality*Critical Care Medicine, 2011
- Goal-directed haemodynamic therapy and gastrointestinal complications in major surgery: a meta-analysis of randomized controlled trialsBritish Journal of Anaesthesia, 2009
- Hydroxyethyl StarchesAnesthesiology, 2009
- Crystalloid or colloid fluid loading and pulmonary permeability, edema, and injury in septic and nonseptic critically ill patients with hypovolemia*Critical Care Medicine, 2009
- Fluid resuscitation in the management of early septic shock (FINESS): a randomized controlled feasibility trialCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 2008
- A Rational Approach to Perioperative Fluid ManagementAnesthesiology, 2008